Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Non-Current Debt (2016 - 2025)

Coherus Oncology's Non-Current Debt history spans 10 years, with the latest figure at $37.1 million for Q4 2025.

  • For Q4 2025, Non-Current Debt rose 0.96% year-over-year to $37.1 million; the TTM value through Dec 2025 reached $37.1 million, up 0.96%, while the annual FY2025 figure was $37.1 million, 0.96% up from the prior year.
  • Non-Current Debt for Q4 2025 was $37.1 million at Coherus Oncology, roughly flat from $37.0 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $246.5 million in Q4 2023 and bottomed at $36.5 million in Q2 2024.
  • The 5-year median for Non-Current Debt is $73.6 million (2021), against an average of $123.4 million.
  • The largest annual shift saw Non-Current Debt surged 323.39% in 2022 before it plummeted 85.14% in 2024.
  • A 5-year view of Non-Current Debt shows it stood at $75.5 million in 2021, then skyrocketed by 225.09% to $245.5 million in 2022, then rose by 0.41% to $246.5 million in 2023, then plummeted by 85.11% to $36.7 million in 2024, then increased by 0.96% to $37.1 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Non-Current Debt are $37.1 million (Q4 2025), $37.0 million (Q3 2025), and $36.9 million (Q2 2025).